Human Papillomavirus (HPV) vaccination in Africa: Urgent steps needed to address low uptake amid rising hesitancy
HPV is fuelling high cervical cancer rates in sub-Saharan Africa despite the availability of effective vaccines. Yet uptake remains low, driven largely by vaccine hesitancy. In South Africa alone, most participants (71%) were hesitant to receive at least one of the vacines in the country, according to the Vaccine Confidence Report by MSD (www.MSD.co.za) and Prof. Hannelie Meyer, Head of the South African Vaccination and Immunisation Centre. [1] The report was launched at the European Society of Clinical Microbiology and Infectious Diseases and during the SSA HPV Media Roundtable held during World and Africa Immunisation Week (24–30 April 2025).
Cervical cancer, caused by persistent infection of HPV, is one of the leading causes of cancer-related deaths among women in sub-Saharan Africa. The World Health Organization (WHO) estimates that 94% of global cervical cancer deaths occur in low- and middle-income countries, with sub-Saharan Africa heavily affected. [2]
Studies indicate that, globally, about 12% of women with normal cervical cytology are found to have an HPV infection. This prevalence doubles to around 24% in sub-Saharan Africa. Young women under 25 are particularly vulnerable, with an HPV prevalence rate of 43.9% in Africa compared to the global rate of 19.2%. [3]
A 2023 report indicated that cervical cancer ranks as the 13th most frequent cancer among women in Egypt and the 9th most frequent among women aged 15 to 44 years. [4] In Kigali, Rwanda, before the national HPV vaccination programme, 54% of women aged 19 years and younger were found to have received an HPV-positive result. [5] The high mortality rate in Ghana further demonstrates the burden, with approximately 3,000 women diagnosed with cervical cancer annually, resulting in around 2,000 deaths each year. [6]
Vaccine hesitancy, defined as a delay in acceptance or refusal of vaccines despite their availability, remains a challenge in the fight against preventable diseases such as cervical cancer. Misinformation, cultural beliefs, and accessibility issues further compound the low uptake of HPV vaccines. As global health organisations and local health authorities strive to eliminate preventable diseases, understanding and addressing vaccine hesitancy has never been more urgent. [1]
Understanding vaccine hesitancy
The Vaccine Confidence Report highlights several drivers of HPV vaccine hesitancy, including safety concerns, mistrust in healthcare systems, and misinformation on social media. According to Prof. Meyer, despite clear scientific evidence, many still believe vaccines are harmful. [1] 'This reluctance is troubling,' she said, 'given the direct link between HPV and cervical cancer. Addressing these fears with credible information is vital to reducing the burden in sub-Saharan Africa.'
An external study titled 'Vaccine Hesitancy and Trust in sub-Saharan Africa' published in Scientific Reports in May 2023 examined vaccination behaviours and attitudes across six sub-Saharan African countries: Ghana, Kenya, Nigeria, South Africa, Tanzania, and Uganda. The study found that only about 10% of respondents reported receiving at least one HPV vaccination. Vaccine hesitancy rates varied across countries, with South Africa exhibiting the highest rate at 17.15% and Kenya the lowest at 8.3%. [7]
Impact of misinformation, funding gaps and immunisation disruption Misinformation remains a major driver of vaccine hesitancy in Africa, especially through online platforms. It has shaped public attitudes and eroded trust in immunisation programmes. At the same time, shifting global priorities and economic pressures have led to reduced funding for vaccination efforts, limiting access in low-income communities. [8] 'Routine immunisation has saved millions of lives,' said Dr Alima Essoh, Regional Director of the Preventive Medicine Agency for Africa (AMP Africa). 'When misinformation and resource constraints disrupt these efforts, we risk undoing decades of progress.' Expanding HPV vaccination is critical to reducing cervical cancer, but it requires tackling misinformation head-on and improving access across the continent.
Broader implications for public health
While HPV vaccination remains a key focus, vaccine hesitancy extends to other preventable diseases. The World Health Organization (WHO) has set a target to eliminate cervical cancer as a public health concern by 2030, which includes ensuring that 90% of girls are fully vaccinated against HPV by age 15. [9] According to Prof Meyer, vaccine hesitancy threatens to derail this goal and broader efforts to achieve high immunisation rates for other preventable illnesses such as measles, polio, and influenza.
Rethinking the fight against HPV-related cervical cancer: Community action and vaccine confidence
Efforts to eliminate HPV and reduce HPV-related cervical cancer in Africa necessitate innovative, community-driven solutions. Dr Sabrina Kitaka, Senior Lecturer at Makerere University, states that engaging and accessible tools, such as comic books and school-based vaccination, have significantly enhanced vaccine uptake among young people. She adds that reminder systems, such as SMS and automated phone calls, help ensure adolescents complete the HPV vaccine schedule. If implemented on a large scale, these strategies could strengthen vaccine coverage across the region. She further states that, tackling vaccine hesitancy will require a coordinated approach involving governments, healthcare workers, civil society, and the private sector. This means improving health communication, building trust through local partnerships, and tailoring outreach to meet communities where they are.
'There is no time to waste,' says Prof. Meyer. 'We must work together to share accurate information, address concerns, and make vaccines truly accessible. Only then can we protect future generations from preventable diseases.'
Disclaimer: The views and opinions expressed by the speakers in this document are their own and do not necessarily reflect the views or positions of MSD.
References
MSD South Africa., Meyer, JC. 2025. Vaccination Hesitancy Study. Accessed 07 April 2025 'Human papillomavirus and cancer', World Health Organization, 5 March 2024: http://apo-opa.co/3Glx3fK. High Burden of Human Papillomavirus (HPV) Infection Among Young Women in KwaZulu-Natal, South Africa' PLOS One, 19 January 2016: https://apo-opa.co/4cTdfNc. Accessed 07 April 2025. 'Egypt HPV and Related Cancers, Fact sheet 2023, https://apo-opa.co/3YMStZv? Accessed 2 April 2025. 'Human papillomavirus infection in Rwanda at the moment of implementation of a national HPV vaccination programme', National Library of Medicine, National Centre for Biotechnology Information, 24 May 2016: https://apo-opa.co/4jORArD. Accessed 07 April 2025. 'Human Papillomavirus and Related Diseases Report', HPV Information Centre, 10 March 2023: https://apo-opa.co/3RzzoGn. Accessed 07 April 2025. 'Vaccine hesitancy and trust in sub-Saharan Africa', Scientific Reports (https://apo-opa.co/4jGlMVQ), 13 May 2024: https://apo-opa.co/4cQyUp9. Accessed 10 April 2025. UNICEF, Global immunization coverage stalled in 2021, leaving millions of children unprotected – WHO and UNICEF, 2022: http://apo-opa.co/3RTv3OB. WHO. HPV&Cancer. Available at: Human papillomavirus and cancer (http://apo-opa.co/4cSGTSM). Accessed: 07 April 2025
REPORT ANY SUSPECTED ADVERSE EVENTS OR PRODUCT QUALITY COMPLAINTS TO DPOC SOUTH AFRICA:
dpoc.zaf@msd.com
Tel: +27 (0)11 655 3000.
www.MSD.co.za
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Zawya
25-04-2025
- Zawya
Vaccination progress helps save millions of lives in African region
An increase in vaccine coverage in Africa is helping protect millions of people from life-threatening diseases such as measles, polio and cervical cancer. In 2023, vaccination saved at least 1.8 million lives in the African region, nearly half the global figure of 4.2 million. These advancements have been possible thanks to government efforts and the support from partners including Gavi, the Vaccine Alliance (Gavi), UNICEF, World Health Organization (WHO) and others. More than 5 million 'zero-dose' children – children who have not received a single dose of an essential routine vaccine – in the African region have been vaccinated since 2024 through the 'Big Catch-Up' initiative launched in 2023 in 24 priority countries to protect communities from vaccine-preventable outbreaks, save children's lives and strengthen national health systems. Despite a growing birth cohort between 2022 and 2023, the region recorded a two-percentage-point increase in the diphtheria-tetanus-pertussis (DTP3) immunization coverage among 1-year-olds, from 72% to 74%, an important sign of recovery in routine immunization services post-COVID-19. This progress means that amid a rising number of births, governments are vaccinating more children each year than ever before. Notable gains were seen in Cameroon, Chad, Côte d'Ivoire, Ethiopia, Madagascar, Malawi, Mozambique and Uganda. In addition, more girls than ever are being protected against cervical cancer, a disease that kills a woman every two minutes worldwide. Human papillomavirus (HPV) vaccination coverage (one dose) has increased to 40% in 2023 up from 28% the year before – making Africa the region with the second highest coverage rate globally, empowering millions of girls to fulfil their potential. Africa has also made tremendous progress in the fight against polio, recording a 93% decline in circulating variant poliovirus type 1 cases from 2023 to 2024 and a 65% decrease in variant poliovirus type 1 cases in just the past year. This year, World Immunization Week/African Vaccination Week, which is being marked under the theme Immunization For All is Humanly Possible, aims to promote the life-saving power of immunization to protect people of all ages against vaccine-preventable diseases. 'We have made great progress in expanding vaccination and saving lives, thanks to the dedication of governments and partners. But we still have more ground to cover. We must sustain and expand these life-saving efforts to build a stronger, healthier future for all,' said Dr Chikwe Ihekweazu, Acting WHO Regional Director for Africa. Despite the progress, challenges persist in reaching children in the region. One in four children remain under-vaccinated (missing out on key routine vaccines) and one out of five children are unvaccinated, with many countries facing recurring outbreaks, particularly of measles – a highly contagious and potentially fatal disease. These gaps, which leave the region vulnerable, can be attributed to persistent barriers including limited access to healthcare in remote areas often due to conflict and instability, logistical and cold chain constraints, vaccine hesitancy driven by misinformation, and insufficient funding for immunization programs. These challenges are further compounded by disruptions caused by public health emergencies. 'The progress seen across African countries—bolstered by an unprecedented record of co-financing toward vaccine programmes in 2024 by African governments—demonstrates the tangible impact of sustained commitment,' said Thabani Maphosa, Chief Country Delivery Officer at Gavi, the Vaccine Alliance. 'However, this momentum must not stall. Conflict, population growth, displacement, and natural disasters are creating ideal conditions for outbreaks to emerge and spread. Investing in immunization and securing sufficient funding for Gavi to carry out its mission over the next five years is essential to protect our collective future.' Building on the gains in Africa, Gavi has launched an ambitious five year strategy, 'Gavi 6.0' which is anchored on three key pillars: protecting the world against pandemics and disease outbreaks; protecting people by vaccinating more children against more diseases than ever before - including reaching 50 million children with the malaria vaccine by 2030; and protecting communities by reducing the number of zero-dose children. A successful replenishment for Gavi will enable the Vaccine Alliance –a coalition of partners that includes 39 African governments - to implement this impactful 6.0 strategy and will enable countries to protect and advance the progress that has been made to date. Full engagement across the Alliance to obtain the necessary funding over the next few months will be critical. 2025 also marks the mid-point of the Immunization Agenda 2030, which aims to prevent diseases, promote equity and build strong immunization programmes. To achieve these goals, African governments and partners are encouraged to accelerate progress towards reducing zero-dose children, increase routine immunisation coverage, accelerate malaria vaccine introductions and expand access to HPV vaccines. Maintaining the progress achieved in immunization over the years will also require regional commitment to implement key strategies. These include increasing investment in health systems and infrastructure for effective vaccine delivery; enhancing surveillance systems to respond swiftly to outbreaks; addressing vaccine hesitancy and misinformation; bolstering domestic funding for immunization programmes; increasing the use of innovation and technology for better vaccine delivery; and investing in research and development for vaccine development. In 2024, Gavi and partners launched the African Vaccine Manufacturing Accelerator (AVMA), a financing mechanism established to make up to US$ 1.2 billion available over ten years to accelerate the expansion of commercially viable vaccine manufacturing in Africa. Two new collaborations under this initiative were signed earlier this year, in a positive step towards enhanced regional health security. Distributed by APO Group on behalf of WHO Regional Office for Africa.
Zawya
24-04-2025
- Zawya
Human Papillomavirus (HPV) vaccination in Africa: Urgent steps needed to address low uptake amid rising hesitancy
HPV is fuelling high cervical cancer rates in sub-Saharan Africa despite the availability of effective vaccines. Yet uptake remains low, driven largely by vaccine hesitancy. In South Africa alone, most participants (71%) were hesitant to receive at least one of the vacines in the country, according to the Vaccine Confidence Report by MSD ( and Prof. Hannelie Meyer, Head of the South African Vaccination and Immunisation Centre. [1] The report was launched at the European Society of Clinical Microbiology and Infectious Diseases and during the SSA HPV Media Roundtable held during World and Africa Immunisation Week (24–30 April 2025). Cervical cancer, caused by persistent infection of HPV, is one of the leading causes of cancer-related deaths among women in sub-Saharan Africa. The World Health Organization (WHO) estimates that 94% of global cervical cancer deaths occur in low- and middle-income countries, with sub-Saharan Africa heavily affected. [2] Studies indicate that, globally, about 12% of women with normal cervical cytology are found to have an HPV infection. This prevalence doubles to around 24% in sub-Saharan Africa. Young women under 25 are particularly vulnerable, with an HPV prevalence rate of 43.9% in Africa compared to the global rate of 19.2%. [3] A 2023 report indicated that cervical cancer ranks as the 13th most frequent cancer among women in Egypt and the 9th most frequent among women aged 15 to 44 years. [4] In Kigali, Rwanda, before the national HPV vaccination programme, 54% of women aged 19 years and younger were found to have received an HPV-positive result. [5] The high mortality rate in Ghana further demonstrates the burden, with approximately 3,000 women diagnosed with cervical cancer annually, resulting in around 2,000 deaths each year. [6] Vaccine hesitancy, defined as a delay in acceptance or refusal of vaccines despite their availability, remains a challenge in the fight against preventable diseases such as cervical cancer. Misinformation, cultural beliefs, and accessibility issues further compound the low uptake of HPV vaccines. As global health organisations and local health authorities strive to eliminate preventable diseases, understanding and addressing vaccine hesitancy has never been more urgent. [1] Understanding vaccine hesitancy The Vaccine Confidence Report highlights several drivers of HPV vaccine hesitancy, including safety concerns, mistrust in healthcare systems, and misinformation on social media. According to Prof. Meyer, despite clear scientific evidence, many still believe vaccines are harmful. [1] 'This reluctance is troubling,' she said, 'given the direct link between HPV and cervical cancer. Addressing these fears with credible information is vital to reducing the burden in sub-Saharan Africa.' An external study titled 'Vaccine Hesitancy and Trust in sub-Saharan Africa' published in Scientific Reports in May 2023 examined vaccination behaviours and attitudes across six sub-Saharan African countries: Ghana, Kenya, Nigeria, South Africa, Tanzania, and Uganda. The study found that only about 10% of respondents reported receiving at least one HPV vaccination. Vaccine hesitancy rates varied across countries, with South Africa exhibiting the highest rate at 17.15% and Kenya the lowest at 8.3%. [7] Impact of misinformation, funding gaps and immunisation disruption Misinformation remains a major driver of vaccine hesitancy in Africa, especially through online platforms. It has shaped public attitudes and eroded trust in immunisation programmes. At the same time, shifting global priorities and economic pressures have led to reduced funding for vaccination efforts, limiting access in low-income communities. [8] 'Routine immunisation has saved millions of lives,' said Dr Alima Essoh, Regional Director of the Preventive Medicine Agency for Africa (AMP Africa). 'When misinformation and resource constraints disrupt these efforts, we risk undoing decades of progress.' Expanding HPV vaccination is critical to reducing cervical cancer, but it requires tackling misinformation head-on and improving access across the continent. Broader implications for public health While HPV vaccination remains a key focus, vaccine hesitancy extends to other preventable diseases. The World Health Organization (WHO) has set a target to eliminate cervical cancer as a public health concern by 2030, which includes ensuring that 90% of girls are fully vaccinated against HPV by age 15. [9] According to Prof Meyer, vaccine hesitancy threatens to derail this goal and broader efforts to achieve high immunisation rates for other preventable illnesses such as measles, polio, and influenza. Rethinking the fight against HPV-related cervical cancer: Community action and vaccine confidence Efforts to eliminate HPV and reduce HPV-related cervical cancer in Africa necessitate innovative, community-driven solutions. Dr Sabrina Kitaka, Senior Lecturer at Makerere University, states that engaging and accessible tools, such as comic books and school-based vaccination, have significantly enhanced vaccine uptake among young people. She adds that reminder systems, such as SMS and automated phone calls, help ensure adolescents complete the HPV vaccine schedule. If implemented on a large scale, these strategies could strengthen vaccine coverage across the region. She further states that, tackling vaccine hesitancy will require a coordinated approach involving governments, healthcare workers, civil society, and the private sector. This means improving health communication, building trust through local partnerships, and tailoring outreach to meet communities where they are. 'There is no time to waste,' says Prof. Meyer. 'We must work together to share accurate information, address concerns, and make vaccines truly accessible. Only then can we protect future generations from preventable diseases.' Disclaimer: The views and opinions expressed by the speakers in this document are their own and do not necessarily reflect the views or positions of MSD. References MSD South Africa., Meyer, JC. 2025. Vaccination Hesitancy Study. Accessed 07 April 2025 'Human papillomavirus and cancer', World Health Organization, 5 March 2024: High Burden of Human Papillomavirus (HPV) Infection Among Young Women in KwaZulu-Natal, South Africa' PLOS One, 19 January 2016: Accessed 07 April 2025. 'Egypt HPV and Related Cancers, Fact sheet 2023, Accessed 2 April 2025. 'Human papillomavirus infection in Rwanda at the moment of implementation of a national HPV vaccination programme', National Library of Medicine, National Centre for Biotechnology Information, 24 May 2016: Accessed 07 April 2025. 'Human Papillomavirus and Related Diseases Report', HPV Information Centre, 10 March 2023: Accessed 07 April 2025. 'Vaccine hesitancy and trust in sub-Saharan Africa', Scientific Reports ( 13 May 2024: Accessed 10 April 2025. UNICEF, Global immunization coverage stalled in 2021, leaving millions of children unprotected – WHO and UNICEF, 2022: WHO. HPV&Cancer. Available at: Human papillomavirus and cancer ( Accessed: 07 April 2025 REPORT ANY SUSPECTED ADVERSE EVENTS OR PRODUCT QUALITY COMPLAINTS TO DPOC SOUTH AFRICA: Tel: +27 (0)11 655 3000.
Al Etihad
14-04-2025
- Al Etihad
Denmark could eradicate cervical cancer by 2040: Study
14 Apr 2025 14:14 Copenhagen (AFP)Denmark aims to eradicate cervical cancer by 2040 thanks to a national HPV vaccination campaign and screening programme, the Danish Cancer Society said on Monday."Even before 2040, so few women may have the disease that it may be considered eradicated," the Danish Cancer Society said in a statement."It would be the first time a cancer has disappeared," it current cervical cancer rate in Denmark is lower than 10 out of 100,000 women, according to a study in the Danish medical journal Ugeskrift for to the World Health Organization's (WHO) criteria, the disease would be considered eradicated when there is an incidence rate lower than four per 100,000 Denmark, the vaccination rate against human papillomavirus (HPV), the main cause of the disease, is 89% for girls and boys aged 12, for the first of two doses. That's just shy of the 90% free vaccine was introduced for girls in 2008-2009 and for boys in addition, 60% of women in Denmark accept the offer of free screenings, slightly lower than the 70% participation target. Neighbouring Sweden could however beat Denmark to the post: it aims to eradicate cervical cancer by 2027, according to the Regional Cancer Centres in Sweden.
